MVIS US Listed Pharmaceutical 25 Index

The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 218 million in assets under management.

Financial Products

A licence agreement is required to use our indices, index data or trademark for any commercial purpose, or for research and analysis, or for the issuance, launch, promotion or marketing of financial products such as exchange-traded products, mutual funds, certificates, derivatives, swaps, bonds or OTC products linked to or based on MVIS indices. Please contact us for information on obtaining a licence.

The MVIS US Listed Pharmaceutical 25 Index Index is currently licensed to underlie the following products:

  • VanEck Vectors Pharmaceutical ETF